Close menu




November 10th, 2021 | 12:53 CET

AMD, BrainChip, Nvidia - Profiting from Artificial Intelligence

  • Technology
Photo credits: pixabay.com

The first research into artificial intelligence (AI) began in the 1950s, but it was quite a while before any real progress was seen. This was largely due to ever-faster processors that could process even the largest amounts of data much faster than the old mainframes. We can see what artificial intelligence is capable of in digital assistants like Siri, Alexa, or translation programs like Google. In the coming years, artificial intelligence will penetrate more and more areas and automate many processes that were unthinkable until recently. Today we analyze three companies that produce hardware for the AI sector.

time to read: 4 minutes | Author: Armin Schulz
ISIN: ADVANCED MIC.DEV. DL-_01 | US0079031078 , BRAINCHIP HOLDINGS LTD | AU000000BRN8 , NVIDIA CORP. DL-_001 | US67066G1040

Table of contents:


    AMD - Deal with Meta causes share price fireworks

    AMD supplies its customers with hardware for the data centers where artificial intelligence processes incoming information. There, high-performance computing solutions are needed to carry out the multitude of computing tasks in parallel. These data centers then often offer cloud services, which has the advantage for customers that they do not have to purchase and maintain their own infrastructure. With the AMD EPYC processor, the Company has probably the fastest processor in the world currently.

    That might also be one of the reasons why Meta, formerly Facebook, has chosen AMD as a supplier for its servers. An adapted third-generation EPYC processor will be used there. Last week's quarterly figures already showed how well the Company is currently doing. The analysts' expectations were exceeded, and the turnover increased by 54% to USD 4.31 billion, and the profit was USD 0.73 per share. Experts had expected 6 cents less.

    The deal with Meta will undoubtedly make it easier for the Company to win over major customers in the future. The newly fueled crypto hype will also keep GPU sales numbers high in the future. Since the beginning of October, the stock has been able to gain from around USD 100 to currently USD 150.16. As an interested investor, you should wait for a setback before getting in.

    BrainChip - Akida sale has started

    Australian Company BrainChip is taking a different approach to traditional AI. In so-called Edge-AI, i.e. Artificial Intelligence on Internet-of-Things or mobile devices, one supports the processing of data using AI on the device itself. The advantages are obvious. No Internet connection is required. The data does not have to be sent to the cloud for processing first. Thus, the technology can calculate faster. It also only reacts when an event occurs, which saves power. In addition, data security is significantly higher.

    For this purpose, the Company has developed the Akida chip, which masters neuromorphic computing and imitates the human brain, thus learning and processing information. The chip does not need a CPU but works autonomously, requires little power, generates hardly any heat and is secure from a data protection point of view because no data is passed on to the outside. On October 20, the Company was able to announce the start of sales for two development kits. There is both an x86 PC development kit and an ARM-based model on the Raspberry Pi.

    The application areas for Akida range from autonomous driving to security technology, medical devices, IoT devices, industrial robots and safety technology. On the one hand, BrainChip wants to sell the chips; on the other hand, it wants to put the intellectual property in the hands of manufacturers, who then have to pay royalties to the Company. The stock has also been traded on the OTCQX Best Market in the US since November 3. The security has already jumped with news of the sales start and is currently trading at 0.51 Australian dollars (AUD). If larger orders or licenses are announced, the high for the year at AUD 0.77 is likely to be tested.

    Nvidia - BEYOND event shows the vision of the future

    Nvidia has long been considered a graphics card maker, but even though that business is still humming, another area has increasingly worked its way to the forefront, artificial intelligence. The Company has created a Data Center division that will replace the graphics card division as the revenue driver. Whether it's Deep Learning or Artificial Intelligence, Nvidia's hardware handles the tasks. With the takeover of ARM, another step would be taken in the direction of leadership in AI. However, the deal has not yet received final approval from the authorities.

    At the virtual BEYOND event on November 9, Raymond Teh, Nvidia's vice president of sales and marketing, presented his visions for the Company's future. In AI, he sees the development of autonomous driving dominating every car in the future. The Company then announced that it is now possible to develop personal assistants and chatbots using AI with the help of the NeMo Megatron framework. These AI avatars get a face with Omniverse and can be available to customers virtually around the clock. It also unveiled a new Superswitch that has not only more power but also uses less power.

    In the future, the Company still wants to offer cloud gaming and thus further boost the growing data center business. Further growth is also possible in graphics cards with the new Bitcoin hype. Since the beginning of October, the stock has risen a good 50% and is currently trading at USD 308.04. As with AMD, it is important to wait for a setback here first.


    In the long term, artificial intelligence will influence our everyday lives more and more. Therefore, such promising shares belong in every portfolio. AMD is currently benefiting from its fast CPUs and was able to win a renowned partner in Meta. BrainChip is pursuing a different approach, which is very exciting. Even though the Company is still relatively small, it seems to have a head start on the big players that want to pull everything into the cloud. Nvidia is one of the most prominent AI players. If the takeover of ARM succeeds, the entire value chain will be covered.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read